Abbott Laboratories is down nearly 5% over the past month to $86.67, but company insiders and the Street's bulls are treating the decline as an entry point — even as the options market quietly rotates more bullish than it's been in weeks.
The most noteworthy signal this week is the insider buying. After a broad selloff following the April earnings print, both a director and the CFO stepped in to buy. Independent Director Daniel Starks purchased 10,000 shares at $92.65 on April 27, spending just over $926,000. CFO Philip Boudreau followed with 2,200 shares at $91.50, a $201,000 purchase. Neither is a massive position relative to the company's size, but the CFO's involvement carries weight — he is signing off on the balance sheet and chose to add exposure. Net insider activity over 90 days is modestly positive at roughly $10.9 million, tilted clearly toward buying once the March round of routine executive sales is stripped out. The pattern reads as confidence in the valuation, not a signal of distress.
Options positioning reinforces that cautious-to-improving tone. The put/call ratio has eased to 0.72, below its 20-day average of 0.79 and close to the 52-week low of 0.698. That means call activity is running relatively heavy — not extreme, but the directional tilt has shifted away from the defensive posture that defined options flow back in April and early May, when the PCR sat above 0.97. Short interest is a minor factor here. At 1.35% of the free float, it has edged up about 1% over the past week and roughly 10% from the late-April low, but remains well within normal range for a large-cap healthcare name. Borrow is essentially free at 0.08% per annum, and availability is vast — the lending pool is effectively unconstrained — so there is no pressure building from the short side.
The Street stayed firmly bullish through Abbott's post-earnings target cuts but kept ratings intact across the board. After the Q1 print on April 16 — which saw the stock fall 4.7% on the day and nearly 9% over the following five sessions — analysts at BofA Securities, Stifel, Evercore ISI, RBC Capital, and Piper Sandler all trimmed targets, with cuts ranging from $5 to $30 depending on the firm. Yet every firm maintained a Buy, Overweight, or Outperform rating. The consensus mean target now sits at $118.32, implying roughly 37% upside from current levels. The valuation case has sharpened: the P/E multiple has compressed about 7% over 30 days to 15.2x, and EV/EBITDA has slipped to 11.3x. For a business with Abbott's diversification — spanning diabetes devices, structural heart, diagnostics, and nutrition — those are undemanding multiples by historical standards. The dividend score ranks in the 98th percentile, underlining the income case for long-only holders.
Two positive product catalysts landed this week. Abbott secured CE Mark approval for the world's first dual glucose-ketone sensing technology for diabetes patients, an incremental but meaningful step for the FreeStyle Libre franchise. Separately, an updated American Cancer Society guideline reaffirmed Abbott's leadership position in noninvasive colorectal cancer screening — a high-importance development for the diagnostics pipeline. The company is also presenting 11 new abstracts across its cancer diagnostics portfolio at ASCO 2026, which gives the commercial team a platform heading into the second half. Close peer Stryker was roughly flat on the week, and Insulet edged up 0.9%, while Abbott slipped 2.4% — the underperformance looks more mechanical than fundamental given the news flow.
The Q2 earnings event is pencilled in for July 15, and the key question at that print is whether the diabetes and structural heart segments — the main growth engines flagged by bulls — can offset any continued weakness in diagnostics. That is where the stock score and analyst sentiment will be most sensitive to guidance.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
